The week in pharma: action, reaction and insight – week to July 26, 2024

28 July 2024

By Barbara Obstoj-Cardwell. Editor

On the research front, China’s BioCity Biopharma recently released positive trial results for its ETA antagonist SC0062 in the treatment of chronic kidney disease. Also of note, US pharma giant Merck & Co announced new Phase II/III data demonstrating the promise of its clesrovimab in preventing respiratory syncytial virus (RSV)in infants. Last week saw a batch of second-quarter 2024 financial results reports, including from two of Europe’s largest pharma companies – the UK’s AstraZeneca and France’s Sanofi.

SC0062 trial results highlight BioCity’s potential to differentiate in kidney disease space

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK